When "actionable" genomic sequencing results cannot be acted upon

View online source

Authors:

Zikmund-Fisher, B. J.

Year:

2017

JAMA Oncol

Description

Clinical Sequencing Evidence-Generating Research (CSER) Consortium. Grant number(s): UM1 HG006508

Return to Search Results

Related Publications

Public attitudes challenge clinical practice on genetic risk disclosure in favour of healthcare-provided direct dissemination to relatives
Journal Article

To disclose or not to disclose: Secondary findings of XXY chromosomes
Journal Article

When to disclose a borderline incidental finding
Journal Article

The importance of defining actionability as related to disclosure of secondary findings identified in research
Journal Article

Clarifying the blurry boundaries between research and clinical care
Journal Article

Respecting autonomy and balancing benefits by disclosing the secondary finding of Klinefelter’s
Journal Article

Emergence of hybrid models of genetic testing beyond direct-to-consumer or traditional labs
Journal Article

A public health perspective on a national precision medicine cohort: Balancing long-term knowledge generation with early health benefit
Journal Article

Can precision medicine help achieve the goal of reducing care when the risks exceed the benefits?
Journal Article

"Use it or lose it" as an alternative approach to protect genetic privacy in personalized medicine
Journal Article

Innovating for a just and equitable future in genomic and precision medicine research
Journal Article

Getting it right: How public engagement might (and might not) help us determine what is equitable in genomics and precision medicine
Journal Article

The other side of the self-advocacy coin: How for-profit companies can divert the path to justice in rare disease
Journal Article

Racism and the textures of visibility
Journal Article

The roots of (in)equity in precision medicine: Gaps in the discourse
Journal Article

Overcoming barriers to health equity in precision medicine research
Journal Article

From “inclusion in what” to “equity in what”: (Re)thinking the question of in/equity in precision medicine and health
Journal Article

“Precision medicine” Is genomic medicine
Journal Article

Do medically underserved individuals benefit from participating in All of Us?
Journal Article

Missing the “we” in precision medicine
Journal Article

Precision public health equity: Another utopian mirage?
Journal Article

The urgent need for health data justice in precision medicine
Journal Article

Invisible: People with disability and (in)equity in precision medicine research
Journal Article

Downstream exclusion in rural rare disease precision medicine research
Journal Article

Advocating for a context specific approach to tackle inequities
Journal Article

“All from us” or “All with us”: Addressing precision medicine inequities requires inclusion of intersectionally minoritized populations as partners and project leaders
Journal Article

Moving to equity in the All of Us Research Program
Journal Article

Spotlighting structural constraints on decisions about participation in genomic and precision medicine
Journal Article

Assessing Vietnamese American patient perspectives on population genetic testing in primary care: A community-engaged approach
Journal Article

Developing a process for returning medically actionable genomic variants to Latino patients in a federally-qualified health center

When "actionable" genomic sequencing results cannot be acted upon

Authors:

Year:

Description

Share

Related Publications

Newsletter